Studies on all products.
Studies
Retatrutide:
📑 Published Clinical Studies & Research Papers1) Phase 2 Trial Results – ObesityTriple–Hormone-Receptor Agonist Retatrutide for Obesity Published in The New England Journal of Medicine — key phase-2 results showing substantial weight loss over 48 weeks. 🔗 https://www.nejm.org/doi/full/10.1056/NEJMoa2301972 New England Journal of Medicine • PubMed record: https://pubmed.ncbi.nlm.nih.gov/37366315/ PubMed2) Phase 2 Body Composition SubstudyEffects of retatrutide on body composition Shows differential fat mass effects in type 2 diabetes participants. 🔗 https://pubmed.ncbi.nlm.nih.gov/40609566/ PubMed3) Phase 2 Liver Fat SubstudyTriple hormone receptor agonist retatrutide for metabolic dysfunction Phase 2 substudy in liver steatosis (fat content) context. 🔗 https://www.nature.com/articles/s41591-024-03018-2 Nature4) Retatrutide Clinical Experience & Qualitative InsightsPerceived benefits of treatment for obesity with retatrutide (exit interview study) 🔗 https://www.sciencedirect.com/science/article/pii/S2667368125000646 ScienceDirect5) Systematic / Meta Analysis ReviewsEfficacy and safety of retatrutide for obesity (2025 review article) 🔗 https://pubmed.ncbi.nlm.nih.gov/40728138/ PubMedReview of an investigational drug retatrutide, a novel triple agonist 🔗 https://pubmed.ncbi.nlm.nih.gov/38367045/ PubMed6) Phase 2 Glycemic & Weight DataRetatrutide effects in type 2 diabetes & weight loss 🔗 https://pubmed.ncbi.nlm.nih.gov/37385280/ PubMed🧪 ClinicalTrials.gov Registrations (Ongoing or Completed)
These are the official trial records where you can see protocol details, endpoints, recruitment status, and update history:
1)
Phase 3: TRIUMPH-3 – Cardiovascular & Kidney Events
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Retatrutide on Major Adverse Cardiovascular & Kidney Events
đź”—
https://www.clinicaltrials.gov/study/NCT06383390
2)
Phase 3b Maintenance of Weight Loss – TRIUMPH-6
Randomized study evaluating long-term maintenance of weight reduction with retatrutide
đź”—
https://clinicaltrials.gov/study/NCT06859268
3)
Phase ? Obesity & Overweight (Master Protocol)
Study to Evaluate Efficacy & Safety of Retatrutide in Obesity/Overweight (J1I-MC-GZBJ)
đź”—
https://clinicaltrials.gov/study/NCT05929066